Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

LEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly increase the progression-free survival (PFS) compared to everolimus in lung and thymic carcinoids.

Trial Details

NCT ID
NCT05918302
Phase
PHASE3
Sponsor
Grupo Espanol de Tumores Neuroendocrinos
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • 177Lu-edotreotide
  • Everolimus
Locations (sample)
  • Edegem, Edegem, Belgium|51.15662,4.44504
  • Brussels, Belgium|50.85045,4.34878
  • Liège, Belgium|50.63373,5.56749
  • Dijon, Dijon, France|47.31344,5.01391
  • Bourdeaux, France|44.58582,5.13611

Key Eligibility Criteria

  • Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written informed consent.
  • Patients ≥ 18 years of age.
  • Patients who have histologically confirmed metastatic or locally advanced unresectable well/moderately differentiated; World Health Organization (W…
  • Patients must have the appropriate pathological features based on WHO classification, and description of proliferation activity as indicated by mit…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →